About
Stingray Therapeutics is a clinical-stage biotech company developing Vizenpistat (SR-8541A), a small-molecule ENPP1 inhibitor that reactivates innate immunity via the cGAS-STING pathway to treat multiple solid tumor cancers, currently in Phase 1 and Phase 1b/2 clinical trials.
Explore Stingray Therapeutics's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.